Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreli, provides an interesting investment opportunity, according to one portfolio manager with an expertise in biotech investing. Michael Tung is co-portfolio manager of Turner Medical Sciences Long/Short Fund, which was the top ranked long/short fund in 2015 according to Morningstar, with a return of nearly 18 percent. Shkreli, you may recall, was indicted on a scheme to defraud Retrophin, a company he founded and previously served as CEO. Despite the legal drama, Tung said there is not a lot of risk in owing the stock. ‘The management team there is excellent,’ said Tung. ‘It’s a very interesting company in that they have several orphan assets, orphan drugs. In addition, right now they also have over $250-million in cash.’ Tung said the company is looking to make acquisitions, and will benefit from the decline in market valuations of potential biotech targets.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Video
Replay:Jim Cramer Explains What You Should Watch When Banks Report Earnings
Jim Cramer weighs in on JPMorgan Chase's earnings, the stocks that he's got his eye on and what he's watching closely in the markets.
Stock Investors Beware -- Inflation Incoming, but Rates Will Stay Low
Tariffs and inflation have a complicated relationship. Here's how that affects your stock portfolio.
Why Investors Interested in ESG Investing Should Consider This ETF
Looking to get into ESG investing? Or just looking to diversify your portfolio? Impact Shares CEO Ethan Powell explains why investors should consider the NAACP Minority Empowerment ETF.